Brief: Xspray Pharma Reports On FDA Pre-Approval Inspection
27/06/2025 14:57
June 27 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST: FDA PRE-APPROVAL INSPECTION INSPECTION CONFIRMS PRODUCTION OF DASYNOC IS FULLY COMPLIANT WITH CURRENT GOOD MANUFACTURING PRACTICE STANDARDS Source text: ID:nMFN4z1JWV Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003